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Abstract: To investigate the associations between dietary fatty acids and cholesterol consumption
and stomach cancer (SC), we analyzed data from a population-based case-control study with a total
of 1900 SC cases and 6532 controls. Dietary data and other risk or protective factors were collected by
face-to-face interviews in Jiangsu Province, China, from 2003 to 2010. Adjusted odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated using multiple unconditional logistic regression
models and an energy-adjusted method. The joint associations between dietary factors and known
risk factors on SC were examined. We observed positive associations between dietary saturated fatty
acids (SFAs), monounsaturated fatty acids (MUFAs), and total cholesterol and the development of SC,
comparing the highest versus lowest quarters. Increased intakes of dietary SFAs (p-trend = 0.005;
aOR, 1.11; 95% CI, 1.01–1.22 with a 7 g/day increase as a continuous variable) and total cholesterol
(p-trend < 0.001; aOR, 1.13; 95% CI, 1.06–1.22 with a 250 mg/day increase as a continuous variable)
were monotonically associated with elevated odds of developing SC. Our results indicate that dietary
SFAs, MUFAs, and total cholesterol are associated with stomach cancer, which might provide a
potential dietary intervention for stomach cancer prevention.
Keywords: Case-control study; dietary fatty acids; dietary cholesterol; stomach cancer; China
1. Introduction
Stomach cancer (SC) is ranked as the fifth-most commonly diagnosed cancer and the third leading
cause of cancer deaths worldwide by GLOBOCAN 2018 [1]. In general, the incidence rate of SC is two
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to three times more common in men than in women. The incidence rates of SC in Eastern Asia are
higher than the rates in Northern America, Northern Europe, and Africa. About 44% of the world’s
total stomach cancer diagnosed, and almost half of the world’s total stomach cancer deaths (49.9%)
occurred in China [1]. As the second-most common and the second-most deadly cancer in China [2],
the age-adjusted 5-year survival of stomach cancer is relatively poor, in the range of 30.2–35.9% [3].
The established risk or protective factors for SC include Helicobacter (H.) pylori infection [4], tobacco
smoking [5,6], heavy alcohol consumption [7], and some dietary factors [8]. The stomach is a part of
the digestive system, which processes and digests foods by secreting acid and enzymes. Nutrients
are absorbed in the small intestine, including vitamins, minerals, carbohydrates, fats, and proteins.
Prior studies found that high intakes of dietary salt [9] and red meat [10] were associated with the
development of stomach cancer, while non-starchy vegetables, fruits, and specific micronutrients
(e.g., selenium, zinc), as well as green tea drinking, may be protective factors for the disease [11–15].
Until now, more than 20 types of fatty acids are found in food. Epidemiologic studies have
examined the relationships between various dietary fatty acids consumption and SC. In a meta-analysis
on the relationship between dietary intake of fat and SC with one cohort and 21 case-control studies,
dietary intake of total fat was potentially associated with SC (highest vs. lowest OR = 1.18, 95% CI:
0.999–1.39) [16]. When separated into subtypes of fatty acids, some case-control studies found the
development of SC has been positively linked to the dietary intakes of saturated fatty acids (SFAs) [17–21]
and monounsaturated fatty acids (MUFAs) [17,19]. However, other case-control studies found no
significant associations between dietary SFAs [22–26], MUFAs [18,23,25,26], PUFAs [18–20,23,25],
and the development of stomach cancer. A cohort study among elderly individuals in the U.S. [27]
found that dietary intakes of total fat and selected fat subtypes (SFAs, MUFAs, PUFAs, trans-fat,
and n-3 PUFAs) were not related to the risk of SC. Furthermore, some previous case-control studies
reported negative associations with dietary MUFAs [22] and PUFAs [17,22,28,29]. Similarly, there are
inconsistent results on dietary cholesterol with the development of SC. Positive associations between
intake of dietary cholesterol and the development of SC were reported in some studies [18,20,30],
but not in others [28,31].
Since most of the previous epidemiological studies had relatively small sample sizes and did not
properly adjust for H. pylori infection or other established risk factors, the reported associations might
be either underpowered or confounded. We tested the hypotheses and evaluated associations of total
and subtypes of fatty acids, as well as total cholesterol on the development of SC using the data from a
large population-based case-control study in a Chinese population.
2. Materials and Methods
2.1. Study Population
A population-based case-control study, named Jiangsu Four Cancers (JFC) study, was conducted
in four counties (Dafeng, Ganyu, Chuzhou, Tongshan) in Jiangsu Province, China, to study risk and
protective factors of four top cancers (lung, stomach, esophageal, and liver cancers). The methodological
details and rationales of the JFC study have been published elsewhere [32]. In short, primary stomach
cancer cases were identified from cancer registries of the County Center for Disease Control and
Prevention (CDC) from January 2003 to December 2010. The control group was randomly chosen from
the list of residence registry of each county and initially matched to the corresponding cases for age
(±five years) and gender. All participants were restricted to residents who had lived in the county
for more than five years before the date of stomach cancer diagnosis for the case group or before the
interview date for the control group. We pooled all controls for four types of cancers together in order
to increase the sample size of the control group. A total of 2216 stomach cancer cases and 8019 controls
were recruited (Supplemental Table S1). The JFC study was approved by both Jiangsu CDC and UCLA
institutional review boards. Written informed consents were obtained from all participants before the
epidemiologic data and biological specimen collections.
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2.2. Data Collection
Face-to-face interviews of participants were conducted using a structured questionnaire with
detailed information on (1) demographic features (age, gender, education, family income per year,
and home address, etc.); (2) residence environment factors; (3) health behaviors (dietary history,
life-long history of tobacco smoking, alcohol consumption, green tea drinking, and physical activity);
(4) medical history; (5) occupational exposures; (6) family history of cancer; and (7) reproductive factors
among women. The interviews of the cases took place at their hospital ward or home after they were
reported to the county cancer registry, and those of the controls took place at their home.
Participants were asked to report their general dietary history one year before the diagnosis or the
interview date to capture dietary patterns by using a 90-item food frequency questionnaire (FFQ). For
each food item, participants were asked whether they ever consumed the food or not in the year before
the diagnosis or the interview date. For each food item they consumed, the frequency and portion
size were asked, according to four predefined frequency categories (times per year, times per month,
times per week, and times per day) and one predefined portion size (1 Liang = 50 g). An average daily
intake of each food item was calculated by multiplying the portion size and frequency of consumption
per day.
Non-fasting peripheral blood samples (5–8 mL) were collected after the time of the interview.
Anti-H. pylori antibody immunoglobulin G (anti-H. pylori Ab IgG) was measured among the cases and
the controls using enzyme-linked immunosorbent assays (ELISA) with kits from Beier Bioengineering
(Beijing, China). According to the manufacturer’s instructions, levels of IgG were categorized as
seropositive and seronegative for H. pylori infection according to the cutoff value.
2.3. Dietary Assessments
For each food item in FFQ, a matched food item or list of food items were found in the China Food
Composition (CFC) Tables 2010, released by the China CDC (Institute of Nutrition and Food Safety
2010). For two food items in FFQ could not be matched with the CFC tables, frog and sugar cane, we
employed the Japanese Food Composition Tables for frog and the U.S. Department of Agriculture
(USDA) database for sugar cane. The average daily intake of calories for each food item was estimated
by multiplying the average daily intake of each food by the corresponding calorie value obtained from
the CFC Tables. Then, the total intake of calories per day was calculated by summing up the calories
from all the food items the participants consumed. In the JFC study population, the median of total
intake of calories from food among controls was 1855.0 calories per day. We excluded individuals who
consumed less than 500 or more than 5000 calories per day, and those who ate only less than four food
items (cases = 316, controls = 1487) because their FFQs were considered incomplete. Finally, 1900 SC
cases and 6532 controls remained in our analyses (see Supplemental Figure S1).
We multiplied the average daily intake of each food by the corresponding contents of fatty acids
obtained from the CFC Tables and summed up the values for each participant. Intakes of total fatty
acids (FAs), saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), and polyunsaturated
fatty acids (PUFAs) were estimated. For PUFAs, n-3 fatty acids, including alpha-linolenic acid (ALA),
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA); and n-6 fatty acids, including linoleic
acid (LA) and arachidonic acid (AA) were estimated. We included total fat and cholesterol in data
analyses. We further evaluated the impact of the cumulative ingestion of each type of fatty acids and
total cholesterol on the susceptibility of stomach cancer.
2.4. Statistical Analysis
A chi-square test or t-test was used to compare the distribution of potential risk and protective
factors between cases and controls. The associations between dietary fatty acids, total cholesterol,
and SC, were evaluated and adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were
estimated using multiple unconditional logistic regression models. Potential confounding factors
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included age (years), gender (male vs. female), county (Dafeng, Ganyu, Chuzhou, Tongshan), education
(illiterate, primary, middle, high school or above), income 10 years ago (<1000, 1000 to <1500, 1500 to
<2500, ≥2500 yuan/year), family history of stomach cancer (yes vs. no), tobacco smoking (yes or no and
pack-years), alcohol consumption (ethanol, g/day), total energy intake (kcal/day), dietary sodium intake
(<0.55, 0.55 to <1.04, 1.04 to <1.96, ≥1.96 g/day), H. pylori infection (yes vs. no), physical activity 10 years
ago (yes vs. no), and body mass index (BMI) (<18.5, 18.5 to <24, 24 to <28, ≥28 kg/m2). To reduce
extraneous variations, we analyzed dietary intakes of fatty acids and cholesterol adjusted for total
energy intake using the residual method [33]. Adjusted ORs and 95% CIs of energy-adjusted dietary
factors for SC were calculated by multiple unconditional logistic regression models. Dietary intakes
of fatty acids and cholesterol were examined as both categorical variables and continuous variables.
Dietary intakes of these nutrients were categorized as quartiles, according to their distributions among
controls. Trend analyses were performed by scoring the ordinal level of dietary exposures (0, 1, 2,
3) and treating them as a continuous variable in the models. For continuous variables, the rescaling
units were chosen based on the interquartile range (IQR) of controls as well as on the availability
of intervention ranges. The 2016 Chinese Dietary Guidelines [34] recommended no more than 25 g
ethanol/day for men and 15 g ethanol/day for women. Three groups of alcohol consumption were
created by the recommendation: never (0 g ethanol/day), low-risk (≤25 g ethanol/day for men and
≤15 g ethanol/day for women), and high-risk (>25 g ethanol/day for men and >15 g ethanol/day for
women).
The interactions among selected dietary factors (SFAs, MUFAs, and total cholesterol) and known
risk factors, including tobacco smoking, alcohol drinking, H. pylori infection, dietary sodium intake,
and family history of stomach cancer, were assessed based on the additive and multiplicative scales [35].
Stratified analyses of these factors were also conducted. The medians in controls were applied
to dichotomize dietary ingestion of SFAs (7.14 g/day), MUFAs (9.85 g/day), and total cholesterol
(207.21 mg/day) in both interaction and stratified analyses. Covariates considered as potential
confounders or effect measure modifiers for analyses were identified based on a priori knowledge of
the risk and protective factors for stomach cancer and by using a directed acyclic graph (DAG).
Furthermore, sensitivity analyses were conducted regarding potential selection bias, multiple
comparison issues, and imputations of missing data. First, we analyzed data based on a direct
interview by excluding the data obtained by proxy interviews (Supplemental Table S2). We also
excluded participants with reported total energy intake in the upper and lower 2.5% of values to this
study [36] (cases = 309, controls = 1421) in data analyses to test for potential selection bias due to
different exclusion criteria of total energy intake (Supplemental Table S3). To reduce potential false
positive or inflated coefficient estimates of multiple comparisons, we used a semi-Bayes shrinkage
method [37], leading to more conservative measurements (Supplemental Table S4). A total of 19% of
participants did not have values for the H. pylori infection test, and total missing values for all variables
were more than 20%. Multiple imputations of the Markov chain Monte Carlo (MCMC) method were
used to impute values of each covariate in the full dataset (cases = 2216, controls = 8019) to maximize
the use of available information if missing data are at random. We applied PROC MI (analysis of
imputed data sets) in the SAS program (version 9.4, Cary, NC, USA) to specify the imputation model,
and created ten imputed datasets. The variables in the imputation model included the outcome, and
the covariates were the same as in the logistic regression models (Supplemental Table S4). Similar
patterns of estimated ORs and 95% CIs were found in the multiple logistic regression models using the
standard method, energy-adjusted method, semi-Bayes shrinkage method, and multiple imputation
method. Therefore, we only present the results using the standard approach and the energy-adjusted
method. All analyses were conducted using SAS.
3. Results
The distributions of demographic characteristics, behavioral variables, total energy intake,
and H. pylori infection among the stomach cancer cases (n = 1900) and controls (n = 6532) are
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summarized in Table 1. In brief, the cases and controls had similar distributions of gender, age, physical
activity 10 years ago, and total energy intake. However, clear differences were observed regarding the
county of residence, education level, income 10 years ago, body mass index (BMI), dietary sodium
intake, tobacco smoking, alcohol consumption, family history of SC, and H. pylori infection. Compared
to the control group, the cases were more likely to have a lower education level, lower income 10 years
ago, and lower BMI level. The cases had the higher intake of dietary sodium and pack-year of tobacco
smoking. Also, the proportions of high-risk drinking status, H. pylori infection, and having a family
history of SC among the cases were higher than those of the controls.
Table 1. Demographic characteristics of stomach cancer and population controls among participants
(cases = 1900, controls = 6532).
Variables Stomach Cancer (n = 1900) n (%) Controls (n = 6532) n (%) p-Value a
Study area
Dafeng 641 (33.7) 2508 (38.4)
Ganyu 527 (27.7) 1872 (28.7)
Chuzhou 454 (23.9) 1109 (17.0)
Tongshan 278 (14.6) 1043 (16.0) <0.001
Gender
Male 1401 (73.7) 4713 (72.2)
Female 499 (26.3) 1819 (27.9) 0.17
Age
Mean (SD) 64.1 (10.8) 64.0 (11.3) 0.73
<50 185 (9.7) 699 (10.7)
50 to <60 407 (21.4) 1450 (22.2)
60 to <70 652 (34.3) 2109 (32.3)
≥70 656 (34.5) 2274 (34.8) 0.31
Education level
Illiterate 954 (50.2) 3215 (49.2)
Primary school 663 (34.9) 2027 (31.0)
Middle school 224 (11.8) 1007 (15.4)
High school or above 55 (2.9) 270 (4.1)
Missing 4 (0.2) 13 (0.2) <0.001
Income 10 years ago (Yuan/year)
<1000 465 (24.5) 1393 (21.3)
1000 to <1500 383 (20.2) 1218 (18.7)
1500 to <2500 496 (26.1) 1707 (26.1)
≥2500 502 (26.4) 2116 (32.4)
Missing 54 (2.8) 98 (1.5) <0.001
Body mass index (kg/m2)
<18.5 298 (15.7) 410 (6.3)
18.5 to <24 1277 (67.2) 3970 (60.8)
24 to <28 255 (13.4) 1743 (26.7)
≥28 61 (3.2) 372 (5.7)
Missing 9 (0.5) 37 (0.6) <0.001
Exercise 10 years ago
No 1304 (68.6) 4564 (69.9)
Yes 596 (31.4) 1968 (30.1) 0.3
Total energy intake (kcal/day)
<1549.3 433 (22.8) 1633 (25.0)
1549.3 to <2036.8 487 (25.6) 1633 (25.0)
2036.8 to <2624.6 468 (24.6) 1633 (25.0)
≥2624.6 512 (27.0) 1633 (25.0) 0.14
Dietary sodium intake (g/day)
<0.55 367 (19.3) 1633 (25.0)
0.55 to <1.04 504 (26.5) 1633 (25.0)
1.04 to <2.00 479 (25.2) 1633 (25.0)
≥2.00 550 (29.0) 1633 (25.0) <0.001
Tobacco smoking
Never 734 (38.6) 3136 (48.0)
Ever 1166 (61.4) 3396 (52.0) <0.001
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Table 1. Cont.
Variables Stomach Cancer (n = 1900) n (%) Controls (n = 6532) n (%) p-Value a
Pack-years of tobacco smoking
0 734 (38.6) 3136 (48.0)
1 to <20 219 (11.5) 746 (11.4)
20 to <40 303 (16.0) 1028 (15.7)
≥40 477 (25.1) 1139 (17.4)
Missing 167 (8.8) 483 (7.4) <0.001
Alcohol drinking
Never 903 (47.5) 3223 (49.3)
Ever 997 (52.5) 3309 (50.7) 0.02
Grams ethanol/day in the 1990s b
Never 1034 (54.4) 3692 (56.5)
Low–risk 132 (7.0) 495 (7.6)
High–risk 705 (37.1) 2209 (33.8)
Missing 29 (1.5) 136 (2.1) 0.03
Family history of stomach cancer
No 1711 (90.1) 6170 (94.5)
Yes 189 (10.0) 362 (5.5) <0.001
H. pylori infection
Negative 332 (17.5) 1613 (24.7)
Positive 1062 (55.9) 3811 (58.3)
Missing 506 (26.6) 1108 (17.0) <0.001
a Based on the chi-square test; t-test for the mean. b Never (0 g ethanol/day); low-risk drinking: men (≤25 g
ethanol/day) and women (≤15 g ethanol/day); high-risk drinking: men (>25 g ethanol/day) and women (>15 g
ethanol/day) based on the 2016 Chinese Dietary Guidelines.
Table 2 shows the median values of dietary fatty acids and total cholesterol intake among the
controls in this population using both non-adjusted and energy-adjusted methods. The median intakes
of total fatty acids were 24.75 g/day for non-adjusted and 36.66 g/day for energy-adjusted methods.
SFAs (median, 7.14 g/day for non-adjusted vs. 10.19 g/day for energy-adjusted), MUFAs (median,
9.85 g/day for non-adjusted vs. 15.41 g/day for energy-adjusted), and PUFAs (median, 6.93 g/day for
non-adjusted vs. 9.64 g/day for energy-adjusted) were the main contributors to total fatty acids. n-3
(median, 0.96 g/day for non-adjusted vs. 1.59 g/day for energy-adjusted) and n-6 PUFAs (median,
5.97 g/day for non-adjusted vs. 8.05 g/day for energy-adjusted) were main contributors to PUFAs in
this population. LA (median, 5.50 g/day for non-adjusted vs. 7.17g/day for energy-adjusted) was
mainly consumed as n-6 PUFAs, and ALA (median, 0.93 g/day for non-adjusted vs. 1.53 g/day for
energy-adjusted) was mainly consumed as n-3 PUFAs. The median ratio of n-3 and n-6 PUFAs was 0.16
for the non-adjusted method and 0.20 for the energy-adjusted method. The median of dietary cholesterol
was 207.21 mg/day for the non-adjusted method and 161.49 mg/day for the energy-adjusted method.
The associations between dietary fatty acids and total cholesterol intakes based on the quartile
distribution and SC are presented in Table 3. A positive association between dietary intake of total
cholesterol and SC was observed comparing the highest quartile to the lowest quartile in the standard
logistic regression model (aOR, 1.57; 95% CI, 1.26–1.96) and in the energy-adjusted model (adjusted
odds ratios with residual method (rOR), 1.56; 95% CI, 1.23–1.93). Increased dietary intake of total
cholesterol showed consistent dose-response associations with the increased odds of developing SC in
both the standard logistic regression model and energy-adjusted model. Nevertheless, there was a
weak or non-linear relationship between total fatty acids and SC. Among the subtypes of dietary fatty
acids, dietary SFAs were positively associated with SC (p-trend = 0.005; aOR, 1.11; 95% CI, 1.01–1.22
with 7 g/day increments as a continuous variable). Dietary MUFAs were positively associated with SC
as a categorical variable, but a null association was observed as a continuous variable. We did not
observe clear associations between dietary intake of PUFAs or their subtypes and stomach cancer.
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Table 2. The medians of dietary fatty acids and cholesterol intakes in controls with a normal range of
total energy intake (n = 6532).
Non-Energy Adjusted Energy-Adjusted (Residual Method)
Variables Median Quartile 1–Quartile 3 Median Quartile 1–Quartile 3
Total fatty acids (g/day) 24.75 14.85–40.17 36.66 27.20–47.48
SFAs (g/day) 7.14 4.35–11.56 10.19 7.59–13.33
MUFAs (g/day) 9.85 5.57–16.65 15.41 11.16–20.56
PUFAs (g/day) 6.93 4.28–10.80 9.64 7.38–12.21
n-6 PUFAs (g/day) 5.97 3.76–9.14 8.05 6.20–10.08
LA (g/day) 5.50 3.49–8.35 7.17 5.58–9.03
AA (g/day) 0.38 0.18–0.78 0.73 0.51–1.03
n-3 PUFAs (g/day) 0.96 0.54–1.70 1.59 1.16–2.12
ALA (g/day) 0.93 0.52–1.64 1.53 1.13–2.05
EPA (mg/day) 10.47 4.30–21.77 19.06 12.47–27.42
DHA (mg/day) 9.97 2.52–24.49 25.96 17.52–37.34
n-3/n-6 PUFAs ratio 0.16 0.13–0.20 0.20 0.18–0.22
Total fat (g/day) 31.07 18.84–48.98 43.39 31.67–57.20
Total cholesterol (mg/day) 207.21 107.24–352.09 161.49 65.98–298.38
Notes: SFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; n-6
PUFAs: including LA and AA; LA: linoleic acid; AA: arachidonic acid; n-3 PUFAs: including ALA, EPA, and DHA;
ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
Table 3. The associations between dietary fatty acids and total cholesterol intakes and stomach cancer
among individuals with a normal range of total energy intake (cases = 1900, controls = 6532).
Variables Cases/Controls aOR (95% CI) a rOR (95% CI) a
Total fatty acid (g/day)
Q1 (<14.85) 356/1633 1.00 1.00
Q2 (14.85 to <24.75) 431/1633 1.28 (1.04, 1.59) 1.20 (0.98, 1.47)
Q3 (24.75 to <40.17) 581/1633 1.58 (1.27, 1.97) 1.39 (1.13, 1.70)
Q4 (>40.17) 532/1633 1.44 (1.10, 1.87) 1.18 (0.95, 1.45)
p-value for trend 0.002 0.08
Per 25 g increase b 1.09 (0.99, 1.19)
SFAs (g/day)
Q1 (<4.35) 361/1633 1.00 1.00
Q2 (4.35 to <7.14) 438/1633 1.26 (1.02, 1.56) 1.20 (0.98, 1.46)
Q3 (7.14 to <11.56) 566/1633 1.48 (1.19, 1.85) 1.37 (1.12, 1.69)
Q4 (>11.56) 535/1633 1.42 (1.09, 1.84) 1.29 (1.04, 1.59)
p-value for trend 0.005 0.01
Per 7 g increase 1.11 (1.01, 1.22)
MUFAs (g/day)
Q1 (<5.57) 356/1633 1.00 1.00
Q2 (5.57 to <9.85) 435/1633 1.19 (0.96, 1.47) 1.14 (0.93, 1.39)
Q3 (9.85 to <16.65) 572/1633 1.50 (1.20, 1.86) 1.43 (1.16, 1.76)
Q4 (>16.65) 537/1633 1.41 (1.09, 1.82) 1.17 (0.95, 1.45)
p-value for trend 0.002 0.05
Per 10 g increase 1.05 (0.97, 1.14)
PUFAs (g/day)
Q1 (<4.28) 365/1633 1.00 1.00
Q2 (4.28 to <6.93) 461/1633 1.21 (0.98, 1.50) 1.17 (0.96, 1.43)
Q3 (6.93 to <10.80) 560/1633 1.47 (1.17, 1.85) 1.20 (0.97, 1.47)
Q4 (>10.80) 514/1633 1.16 (0.88, 1.52) 1.15 (0.93, 1.41)
p-value for trend 0.16 0.23
Per 6 g increase 1.09 (0.99, 1.20)
n-6 PUFAs (g/day)
Q1 (<3.76) 372/1633 1.00 1.00
Q2 (3.76 to < 5.97) 470/1633 1.23 (1.00, 1.52) 1.14 (0.94, 1.39)
Q3 (5.97 to < 9.14) 538/1633 1.36 (1.08, 1.71) 1.08 (0.88, 1.32)
Q4 (>9.14) 520/1633 1.18 (0.90, 1.55) 1.15 (0.94, 1.41)
p-value for trend 0.21 0.28
Per 5 g increase 1.10 (1.00, 1.21)
LA (g/day)
Q1 (<3.49) 380/1633 1.00 1.00
Q2 (3.49 to <5.50) 474/1633 1.25 (1.01, 1.54) 1.14 (0.94, 1.39)
Q3 (5.50 to <8.35) 522/1633 1.26 (1.00, 1.58) 1.06 (0.86, 1.31)
Q4 (>8.35) 524/1633 1.18 (0.90, 1.55) 1.14 (0.93, 1.40)
p-value for trend 0.31 0.32
Per 5 g increase 1.11 (1.00, 1.23)
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Table 3. Cont.
Variables Cases/Controls aOR (95% CI) a rOR (95% CI) a
AA (g/day)
Q1 (<0.18) 394/1633 1.00 1.00
Q2 (0.18 to <0.38) 438/1633 1.12 (0.91, 1.38) 1.08 (0.88, 1.32)
Q3 (0.38 to <0.78) 553/1633 1.26 (1.03, 1.56) 1.26 (1.03, 1.56)
Q4 (>0.78) 515/1633 1.20 (0.95, 1.52) 1.05 (0.86, 1.30)
p-value for trend 0.08 0.40
Per 1 g increase 1.01 (0.90, 1.14)
n-3 PUFAs (g/day)
Q1 (<0.54) 378/1633 1.00 1.00
Q2 (0.54 to <0.96) 417/1633 1.11 (0.90, 1.37) 1.17 (0.95, 1.43)
Q3 (0.96 to <1.70) 595/1633 1.48 (1.19, 1.84) 1.31 (1.07, 1.61)
Q4 (>1.70) 510/1633 1.18 (0.92, 1.53) 1.10 (0.89, 1.35)
p-value for trend 0.05 0.29
Per 1 g increase 1.04 (0.96, 1.13)
ALA (g/day)
Q1 (<0.52) 380/1633 1.00 1.00
Q2 (0.52 to <0.93) 420/1633 1.10 (0.89, 1.35) 1.14 (0.93, 1.40)
Q3 (0.93 to <1.64) 589/1633 1.46 (1.18, 1.82) 1.30 (1.06, 1.60)
Q4 (>1.64) 511/1633 1.17 (0.91, 1.50) 1.07 (0.87, 1.32)
p-value for trend 0.06 0.36
Per 1 g increase 1.04 (0.96, 1.13)
EPA (mg/day)
Q1 (<4.30) 398/1633 1.00 1.00
Q2 (4.30 to <10.47) 503/1633 1.20 (0.98, 1.48) 0.94 (0.77, 1.14)
Q3 (10.47 to <21.77) 450/1633 1.10 (0.88, 1.37) 0.99 (0.80, 1.22)
Q4 (>21.77) 549/1633 1.18 (0.93, 1.49) 1.09 (0.89, 1.33)
p-value for trend 0.37 0.32
Per 20 mg increase 1.00 (0.96, 1.03)
DHA (mg/day)
Q1 (<2.52) 423/1633 1.00 1.00
Q2 (2.52 to <9.97) 448/1633 1.13 (0.91, 1.39) 0.85 (0.70, 1.05)
Q3 (9.97 to <24.49) 443/1633 1.02 (0.81, 1.29) 0.83 (0.67, 1.03)
Q4 (>24.49) 586/1633 1.35 (1.06, 1.72) 1.14 (0.93, 1.40)
p-value for trend 0.03 0.14
Per 20 mg increase 1.04 (1.01, 1.08)
n-3/n-6 PUFAs
Q1 (<0.13) 406/1633 1.00 1.00
Q2 (0.13 to <0.16) 449/1633 1.00 (0.82, 1.23) 0.88 (0.72, 1.08)
Q3 (0.16 to <0.20) 535/1633 1.28 (1.05, 1.56) 1.11 (0.90, 1.34)
Q4 (>0.20) 510/1633 1.13 (0.92, 1.39) 1.09 (0.90, 1.32)
p-value for trend 0.07 0.14
Per 0.1 increase 1.12 (0.98, 1.27)
Total fat (g/day)
Q1 (<18.84) 355/1633 1.00 1.00
Q2 (18.84 to <31.07) 463/1633 1.31 (1.06, 1.61) 1.17 (0.96, 1.43)
Q3 (31.07 to <48.98) 557/1633 1.43 (1.15, 1.78) 1.31 (1.06, 1.61)
Q4 (>48.98) 525/1633 1.30 (1.00, 1.69) 1.10 (0.89, 1.38)
p-value for trend 0.04 0.28
Per 30 g increase 1.04 (0.95, 1.15)
Total cholesterol
(mg/day)
Q1 (<107.24) 407/1633 1.00 1.00
Q2 (107.24 to <207.21) 429/1633 1.06 (0.87, 1.29) 1.17 (0.96, 1.42)
Q3 (207.21 to <352.09) 498/1633 1.32 (1.08, 1.61) 1.45 (1.18, 1.77)
Q4 (>352.09) 566/1633 1.57 (1.26, 1.96) 1.56 (1.27, 1.93)
p-value for trend <0.001 <0.001
Per 250 mg increase 1.13 (1.06, 1.22)
Notes: aOR: adjusted odds ratios; rOR: adjusted odds ratios with residual method; SFAs: saturated fatty acids;
MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; n-6 PUFAs: including LA and AA;
LA: linoleic acid; AA: arachidonic acid; n-3 PUFAs: including ALA, EPA, and DHA; ALA: α-linolenic acid; EPA:
eicosapentaenoic acid; DHA: docosahexaenoic acid; a adjusted for study area, age (continuous), gender (male/female),
education level (illiterate, primary school, middle school, high school or above), income 10 years ago (<1000, 1000 to
<1500, 1500 to <2500, ≥2500), smoking (continuous, pack-years), alcohol consumption (continuous, g ethanol/day),
family history of stomach cancer (yes/no), H. pylori infection (positive/negative), BMI (<18.5, 18.5 to <24, 24 to <28,
≥28), exercise 10 years ago (yes/no), dietary sodium intake (quartile levels of raw for aOR and energy-adjusted for
rOR) and total energy intake (continuous, kcal/day); b The rescaling units for the continuous variables were chosen
based on the interquartile range (IQR) of the controls and feasible intervention ranges.
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The potential interactions were evaluated between dietary intake of SFAs, MUFAs, and total
cholesterol (high vs. low) and known risk factors on stomach cancer, and results were shown in Table 4.
After adjusting for potential confounding factors, we observed dietary intake of SFAs interacted with
tobacco smoking (the ratio of odds ratio (ROR), 0.76; 95% CI, 0.59–0.99), alcohol drinking (ROR, 0.75;
95% CI, 0.57–0.98), and dietary sodium intake (ROR, 0.75; 95% CI, 0.57–0.99) on the development of
stomach cancer at the multiplicative scale of the standard model. Multiplicative interaction between
dietary MUFAs and dietary sodium intake was also observed (ROR, 0.70; 95% CI, 0.53–0.92). However,
we did not identify obvious interactions in the energy-adjusted models.
Table 4. The interactions between dietary intakes of saturated, monounsaturated fatty acids, and total
cholesterol and main risk factors on stomach cancer.
Cases/Controls aOR (95% CI) a rOR (95% CI) a RERI ROR
Tobacco Smoking
Non-smoker Low SFAs 302/1611 1.00 1.00 RERI: −0.27 (−0.67, 0.13) ROR: 0.76 (0.59, 0.99)
Non-smoker High SFAs 432/1525 1.47 (1.18, 1.84) 1.20 (0.98, 1.47) rRERI: 0.10 (−0.24, 0.43) rROR: 1.01 (0.78, 1.31)
Smoker Low SFAs 497/1655 1.65 (1.34, 2.04) 1.41 (1.16, 1.73)
Smoker High SFAs 669/1741 1.86 (1.49, 2.32) 1.71 (1.39, 2.10)
Non-smoker Low MUFAs 298/1597 1.00 1.00 RERI: −0.17 (−0.57, 0.23) ROR: 0.80 (0.62, 1.04)
Non-smoker High MUFAs 436/1539 1.50 (1.20, 1.87) 1.16 (0.95, 1.43) rRERI: 0.17 (−0.16, 0.49) rROR: 1.07 (0.82, 1.38)
Smoker Low MUFAs 493/1669 1.61 (1.30, 1.99) 1.37 (1.12, 1.68)
Smoker High MUFAs 673/1727 1.94 (1.55, 2.42) 1.70 (1.38, 2.09)
Non-smoker Low Cholesterol 325/1600 1.00 1.00 RERI: −0.05 (−0.43, 0.34) ROR: 0.87 (0.67, 1.12)
Non-smoker High Cholesterol 409/1536 1.47 (1.20, 1.80) 1.50 (1.22, 1.83) rRERI: −0.16 (−0.55, 0.24) rROR: 0.81 (0.63, 1.05)
Smoker Low Cholesterol 511/1666 1.53 (1.25, 1.87) 1.58 (1.30, 1.93)
Smoker High Cholesterol 655/1730 1.95 (1.58, 2.40) 1.92 (1.56, 2.36)
Alcohol Drinking
Non-drinker Low SFAs 429/1943 1.00 1.00 RERI: −0.34 (−0.69, 0.01) ROR: 0.75 (0.57, 0.98)
Non-drinker High SFAs 605/1749 1.40 (1.14, 1.72) 1.16 (0.96, 1.40) rRERI: 0.05 (−0.24, 0.34) rROR:1.04 (0.80, 1.35)
Drinker Low SFAs 370/1323 1.23 (0.99, 1.53) 1.03 (0.84, 1.26)
Drinker High SFAs 496/1517 1.29 (1.03, 1.61) 1.24 (1.00, 1.54)
Non-drinker Low MUFAs 429/1927 1.00 1.00 RERI: −0.26 (−0.60, 0.09) ROR: 0.80 (0.61, 1.05)
Non-drinker High MUFAs 605/1765 1.42 (1.16, 1.74) 1.16 (0.96, 1.40) rRERI: 0.06 (−0.23, 0.35) rROR: 1.05 (0.80, 1.37)
Drinker Low MUFAs 362/1339 1.19 (0.95, 1.47) 1.03 (0.84, 1.26)
Drinker High MUFAs 504/1501 1.35 (1.08, 1.69) 1.25 (1.01, 1.55)
Non-drinker Low Cholesterol 463/1932 1.00 1.00 RERI: −0.30 (−0.66, 0.06) ROR: 0.78 (0.60, 1.02)
Non-drinker High Cholesterol 571/1760 1.53 (1.26, 1.84) 1.45 (1.21, 1.74) rRERI: −0.18 (−0.53, 0.17) rROR: 0.85 (0.65, 1.11)
Drinker Low Cholesterol 373/1334 1.18 (0.96, 1.45) 1.14 (0.93, 1.38)
Drinker High Cholesterol 493/1506 1.41 (1.14, 1.75) 1.41 (1.14, 1.74)
H. pylori Infection
Negative Low SFAs 139/861 1.00 1.00 RERI: −0.10 (−0.51, 0.31) ROR:0.87 (0.64, 1.18)
Negative High SFAs 193/752 1.40 (1.05, 1.86) 1.24 (0.94, 1.63) rRERI: 0.02 (−0.35, 0.39) rROR:0.97 (0.71, 1.31)
Positive Low SFAs 436/1873 1.40 (1.11, 1.77) 1.32 (1.05, 1.67)
Positive High SFAs 626/1938 1.70 (1.33, 2.18) 1.59 (1.26, 2.00)
Negative Low MUFAs 138/839 1.00 1.00 RERI: 0.00 (−0.40, 0.39) ROR:0.92 (0.68, 1.26)
Negative High MUFAs 194/774 1.40 (1.05, 1.86) 1.17 (0.89, 1.53) rRERI: 0.13 (−0.22, 0.47) rROR:1.06 (0.78, 1.44)
Positive Low MUFAs 428/1869 1.35 (1.07, 1.71) 1.26 (1.00, 1.58)
Positive High MUFAs 634/1942 1.75 (1.37, 2.24) 1.55 (1.23, 1.95)
Negative Low Cholesterol 134/782 1.00 1.00 RERI: −0.23 (−0.69, 0.24) ROR: 0.78 (0.57, 1.06)
Negative High Cholesterol 198/831 1.66 (1.26, 2.19) 1.68 (1.28, 2.22) rRERI: −0.26 (−0.73, 0.22) rROR: 0.76 (0.56, 1.04)
Positive Low Cholesterol 491/1990 1.49 (1.18, 1.89) 1.50 (1.19, 1.90)
Positive High Cholesterol 571/1821 1.93 (1.52, 2.45) 1.93 (1.52, 2.44)
Dietary Sodium Intake
Low sodium Low SFAs 500/2203 1.00 1.00 RERI: −0.33 (−0.73, 0.05) ROR: 0.75 (0.57, 0.99)
Low sodium High SFAs 371/1063 1.48 (1.20, 1.83) 1.37 (1.12, 1.68) rRERI: −0.25 (−0.61, 0.12) rROR: 0.80 (0.61, 1.05)
High sodium Low SFAs 299/1063 1.31 (1.06, 1.62) 1.29 (1.06, 1.57)
High sodium High SFAs 730/2203 1.45 (1.20, 1.77) 1.41 (1.18, 1.69)
Low sodium Low MUFAs 495/2217 1.00 1.00 RERI: −0.44 (−0.86, −0.03) ROR: 0.70 (0.53, 0.92)
Low sodium High MUFAs 376/1049 1.61 (1.30, 1.98) 1.35 (1.10, 1.65) rRERI: −0.19 (−0.55, 0.17) rROR: 0.83 (0.63, 1.10)
High sodium Low MUFAs 296/1049 1.35 (1.09, 1.67) 1.26 (1.03, 1.53)
High sodium High MUFAs 733/2217 1.51 (1.25, 1.83) 1.42 (1.18, 1.69)
Low sodium Low Cholesterol 495/2108 1.00 1.00 RERI: −0.07 (−0.43, 0.30) ROR: 0.92 (0.70, 1.21)
Low sodium High Cholesterol 376/1158 1.45 (1.18, 1.79) 1.43 (1.17, 1.76) rRERI: −0.03 (−0.39, 0.33) rROR: 0.94 (0.71, 1.23)
High sodium Low Cholesterol 341/1158 1.15 (0.94, 1.40) 1.18 (0.97, 1.43)
High sodium High Cholesterol 688/2108 1.53 (1.27, 1.84) 1.59 (1.32, 1.91)
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Table 4. Cont.
Cases/Controls aOR (95% CI) a rOR (95% CI) a RERI ROR
Family history of stomach cancer
No Low SFAs 728/3120 1.00 1.00 RERI: 0.17 (−0.73, 1.07) ROR: 0.99 (0.62, 1.59)
No High SFAs 983/3050 1.26 (1.06, 1.49) 1.19 (1.02, 1.39) rRERI: 0.43 (−0.45, 1.31) rROR: 1.16 (0.73, 1.83)
Yes Low SFAs 71/146 1.77 (1.21, 2.58) 1.64 (1.18, 2.28)
Yes High SFAs 118/216 2.20 (1.60, 3.03) 2.26 (1.62, 3.16)
No Low MUFAs 720/3111 1.00 1.00 RERI: 0.36 (−0.55, 1.28) ROR: 1.07 (0.66, 1.71)
No High MUFAs 991/3059 1.31 (1.11, 1.55) 1.20 (1.03, 1.40) rRERI: 0.34 (−0.53, 1.22) rROR: 1.10 (0.70, 1.75)
Yes Low MUFAs 71/155 1.70 (1.16, 2.47) 1.67 (1.20, 2.33)
Yes High MUFAs 118/207 2.37 (1.72, 3.26) 2.22 (1.59, 3.09)
No Low Cholesterol 741/3066 1.00 1.00 RERI: 0.46 (−0.51, 1.42) ROR: 1.09 (0.69, 1.73)
No High Cholesterol 970/3104 1.36 (1.17, 1.59) 1.33 (1.14, 1.55) rRERI: 0.99 (−0.15, 2.13) rROR: 1.38 (0.86, 2.22)
Yes Low Cholesterol 95/200 1.69 (1.22, 2.33) 1.58 (1.17, 2.12)
Yes High Cholesterol 94/162 2.51 (1.78, 3.53) 2.90 (1.99, 4.21)
Notes: aOR: adjusted odds ratios; rOR: adjusted odds ratios with residual method; RERI: the relative excess risk due
to interaction; ROR: the ratio of odds ratio; rRERI: RERI with residual method; rROR: ROR with residual method;
SFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; a Adjusted for study area, age (continuous),
gender (male/female), education level (illiterate, primary school, middle school, high school or above), income
10 years ago (<1000, 1000 to <1500, 1500 to<2500, ≥2500), smoking (continuous, pack-years), alcohol consumption
(continuous, g ethanol/day), H. pylori infection (positive/negative), family history of stomach cancer (yes/no),
BMI (<18.5, 18.5 to <24, 24 to <28, ≥28), exercise 10 years ago (yes/no), dietary sodium intake (quartile levels of raw
and energy-adjusted values), total energy intake (continuous, kcal/day), except for the corresponding variables used
for interaction.
In Table 5, we detected heterogeneity of the associations between dietary SFAs and SC across
tobacco smoking (p for heterogeneity = 0.04), alcohol drinking (p for heterogeneity = 0.03), and dietary
sodium intake strata (p for heterogeneity = 0.04) in the standard models, which is consistent with our
observed associations in Table 4. Similarly, heterogeneity of the association between dietary MUFAs
and SC across dietary sodium intake strata was observed (p for heterogeneity = 0.01). Nonetheless,
there was no clear heterogeneity between dietary SFAs, MUFAs, total cholesterol, and SC across the
strata of these risk factors in the energy-adjusted models.
Table 5. The associations between dietary saturated, monounsaturated fatty acids, total cholesterol
(high vs. low) and stomach cancer, stratified by tobacco smoking, alcohol drinking, H. pylori infection,
and dietary sodium intake.
Stratum aOR (95% CI) * p † rOR (95% CI) * p †
Tobacco smoking Never-smokers Ever-smokers Never-smokers Ever-smokers
SFAs 1.43 (1.11, 1.83) 1.13 (0.92, 1.39) 0.04 1.21 (0.97, 1.50) 1.20 (1.00, 1.45) 0.95
MUFAs 1.43 (1.12, 1.82) 1.22 (1.00, 1.50) 0.10 1.16 (0.93, 1.44) 1.24 (1.03, 1.49) 0.63
Total cholesterol 1.36 (1.10, 1.70) 1.34 (1.11, 1.62) 0.28 1.46 (1.18, 1.81) 1.24 (1.03, 1.49) 0.11
Alcohol drinking Non-drinkers Drinkers Non-drinkers Drinkers
SFAs 1.33 (1.07, 1.66) 1.13 (0.88, 1.45) 0.03 1.18 (0.97, 1.43) 1.17 (0.94, 1.47) 0.79
MUFAs 1.33 (1.07, 1.66) 1.24 (0.97, 1.59) 0.11 1.18 (0.97, 1.44) 1.18 (0.94, 1.47) 0.73
Total cholesterol 1.49 (1.22, 1.82) 1.24 (0.99, 1.55) 0.07 1.49 (1.23, 1.81) 1.20 (0.96, 1.50) 0.24
H. pylori infection Negative Positive Negative Positive
SFAs 1.50 (1.06, 2.11) 1.17 (0.97, 1.42) 0.36 1.27 (0.94, 1.71) 1.19 (1.01, 1.41) 0.83
MUFAs 1.46 (1.04, 2.05) 1.26 (1.05, 1.52) 0.62 1.15 (0.85, 1.56) 1.23 (1.04, 1.46) 0.72
Total cholesterol 1.86 (1.37, 2.54) 1.26 (1.07, 1.50) 0.11 1.85 (1.36, 2.50) 1.25 (1.06, 1.48) 0.09
Dietary sodium intake Low High Low High
SFAs 1.40 (1.11, 1.76) 1.16 (0.92, 1.46) 0.04 1.40 (1.14, 1.72) 1.05 (0.85, 1.29) 0.12
MUFAs 1.54 (1.23, 1.94) 1.16 (0.92, 1.45) 0.01 1.38 (1.12, 1.70) 1.08 (0.88, 1.33) 0.21
Total cholesterol 1.39 (1.12, 1.73) 1.35 (1.10, 1.66) 0.55 1.44 (1.16, 1.77) 1.32 (1.08, 1.61) 0.64
Family history of stomach cancer No Yes No Yes
SFAs 1.27 (1.06, 1.51) 1.07 (0.58, 1.97) 0.96 1.20 (1.03, 1.40) 1.39 (0.82, 2.34) 0.54
MUFAs 1.31 (1.11, 1.56) 1.30 (0.71, 2.36) 0.79 1.21 (1.04, 1.41) 1.35 (0.80, 2.26) 0.68
Total cholesterol 1.37 (1.17, 1.60) 1.51 (0.89, 2.54) 0.71 1.34 (1.15, 1.56) 1.74 (1.04, 2.91) 0.18
Notes: aOR: adjusted odds ratios; rOR: adjusted odds ratios with residual method; SFAs: saturated fatty acids;
MUFAs: monounsaturated fatty acids. * Adjusted for study area, age (continuous), gender (male/female), education
level (illiterate, primary school, middle school, high school or above), income 10 years ago (<1000, 1000 to <1500,
1500 to <2500, ≥2500), smoking (continuous, pack-years), alcohol consumption (continuous, g ethanol/day), H. pylori
infection (positive/negative), family history of stomach cancer (yes/no), BMI (<18.5, 18.5 to <24, 24 to <28, ≥28),
exercise 10 years ago (yes/no), dietary sodium intake (quartile levels of raw and energy-adjusted values), total energy
intake (continuous, kcal/day), except for the corresponding variable used for stratification. † Test for heterogeneity
and p < 0.1 was considered statistically significant.
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4. Discussion
In this study, we have observed that higher intakes of dietary SFAs, MUFAs, and total cholesterol
were associated with the development of stomach cancer. The associations were strong with a
dose-response pattern. However, no obvious dose-response relationships were observed between the
consumptions of total fatty acids, PUFAs and their subtypes, and SC. And no consistent interaction or
heterogeneity of the associations was identified between SFAs, MUFAs, total cholesterol, and known
risk factors on SC.
Epidemiological and experimental studies have suggested that different subtypes of fatty acids
appear to play some roles in the carcinogenesis and the development of stomach cancer [38].
Several case-control studies have reported that dietary SFAs were positively associated with stomach
cancer [17–21], which is consistent with our results. However, other case-control studies [22–26] and
one cohort study [27] reported null associations with SFAs. In this study, high intake of dietary MUFAs
showed a positive association with SC, consistent with two previous studies [17,19]. Nevertheless,
the intake of vegetable oils, which is rich in oleic acid, has been inversely associated with SC in three
case-control studies [23,24,39]. The conflicting findings might be associated with a limited sample size
and insufficient adjustment for potential confounding factors and might also be related to the complex
composition of MUFAs. It has been suggested that the various sources of MUFAs, animal fat, and
vegetable oils may differentially affect the association between MUFAs intake and SC [16]. Given that
foods are consumed in combination, variations of MUFAs are highly correlated with other nutrients,
making it difficult to distinguish their individual effects [40].
PUFAs, which are involved in many critical biological functions, are essential nutrients for life,
which cannot be produced endogenously [41]. However, very few studies have comprehensively
investigated the intakes of all PUFA subtypes, n-3 and n-6 PUFAs in particular. In this study, we have
included most of PUFA subtypes and found, when the subtypes of PUFAs were separated, neither n-6
PUFAs (including LA and AA) nor n-3 PUFAs (including ALA, EPA, and DHA) were associated with
SC. Like MUFAs, the different sources of PUFAs might be related to the inconsistent results of PUFAs
on SC. Thiébaut et al. [42] reported that high consumption of alpha-linolenic acid (ALA) from fruit
and vegetables was inversely associated with breast cancer, but ALA from nut mixes and processed
meat was positively related to the disease. PUFAs may also be related to carcinogenic compounds
accumulated along the food chain in the main source of dietary PUFAs [43]. In our study, we found that
the consumption of fresh fish among the cases was higher than those among the controls, which might
be confounded by other factors, such as rich toxins in fresh fish due to water contamination. Therefore,
carefully identifying the sources of dietary fatty acids and minimizing the effects of confounding
factors are necessary and essential for evaluating the association between subtypes of dietary fatty
acids and SC.
Our finding suggests that a high intake of dietary cholesterol may potentially increase the odds
of stomach cancer, which is consistent with three previous case-control studies [18,20,30]. However,
no clear association was discovered in a hospital-based case-control study in Italy (OR, 1.11; 95% CI,
0.94–1.32) [28] and a population-based case-control study in Poland (OR, 0.90; 95%CI, 0.58–1.38) [31].
Most of the prior studies on dietary cholesterol with SC have been conducted in western countries,
where the incidence of SC is relatively low [1], therefore, the power of these studies was low due
to relatively small number of stomach cancer cases, leading to inconsistent findings. The biological
mechanisms on the relationship between dietary intake of cholesterol and stomach cancer have been
hypothesized. Controlled experiments in mice suggest an association between dietary cholesterol
and cancer [44–47]. Hypercholesterolemia, associated with high cholesterol intake, might be linked
to elevated inflammatory activity, which may play a role in cancer development [48]. Jung et al. [49]
also emphasized that hypercholesterolemia was a risk factor for the occurrence of gastric dysplasia.
A preclinical study reported that cholesterol metabolism might play an important role in H. pylori
eradication [50], however, we did not observe any effect measure modification between dietary
cholesterol and H. pylori infection on stomach cancer.
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When we assessed the effect modification of SFAs, MUFAs, and total cholesterol with tobacco
smoking, alcohol drinking, H. pylori infection, dietary sodium intake, and family history of stomach
cancer for the disease, no consistent interactions were identified. The only published paper on the
effect modification of fatty acids by smoking, alcohol, and BMI in the U.S. population [27] concluded
that there was no clear effect modification of dietary fatty acids intake by tobacco smoking and alcohol
drinking on the development of the disease, which is consistent with our results.
The total number of male participants is more than female participants in our study, which
probably reflects the difference in incidence between males and female. From GLOBOCAN 2018,
SC incidences are about 32.1 per 100,000 for men and 13.2 per 100,000 for women in Eastern Asia,
which is consistent with our study [1]. The differences in lifestyle factors, such as diet and smoking, as
well as probable hormonal factors, may explain gender heterogeneity. Future research may focus on
the interactions between gender or hormonal factors and established risk factors on the development
of the disease.
The strengths of this study include a population-based study design, extensive epidemiologic
data including H. pylori infection status and dietary habits, and a large sample size which allow us to
examine both main associations and interactions. However, some potential limitations of the study
should be addressed. Although we collected dietary history one year before the diagnosis for cases
and one year before the interview for controls, the cases might have already changed their dietary
pattern a year before their diagnosis. There might be the possibility of reverse causality between dietary
factors and stomach cancer. However, the majority of dietary fatty acids and cholesterol were from
high-fat foods. These foods might potentially result in stomach upset or gastric reflex, especially in
stomach cancer cases if they had early gastric symptoms, leading to reduced intake of foods with high
fatty acids and cholesterol. If reverse causality does exist, we might observe the inversed association.
Based on the observed positive associations with fatty acids and cholesterol, the possibility of reverse
causality may be minimal.
As with other case-control studies, measurement bias and selection bias are also potential
limitations. The estimations of dietary intake of fatty acids and cholesterol, just like measurements of
other nutrients, are prone to measurement bias. The conversion of food items into related nutrients is
complex, which may lead to measurement errors. To reduce measurement errors, we mainly used
the China Food Composition Tables 2010 to calculate total energy intake and nutrients. For food
items that contained multiple foods (e.g., beef and mutton), we weighted certain foods to reflect more
common consumption or to reflect preparation methods in the population. We also used residual
energy adjustment in the logistic regression models. The results were consistent with those in the
standard logistic regression models.
In this study, the participation rates were 40% among the SC cases and 87% among the controls,
which might lead to potential selection bias. The reason for the low rate is that SC cases diagnosed
at advanced stages were too ill to enroll. Among the recruited cases and controls, the exclusion of
participants who had missing data for diet and other covariates might result in selection bias if data
are not missing completely at random. Hence, sensitivity analyses were performed to test whether
excluding participants with an extreme energy intake would cause potential selection bias. Moreover,
multiple imputations were used in the dietary analyses to compare the imputed estimates against
the complete case analysis. However, we did not find the obvious inconsistent associations when
results from the main analyses were compared with from sensitivity analyses. For confounding
bias, we adjusted for potential confounding factors in all analyses based on prior knowledge and
confounding assessment.
5. Conclusions
The findings from this study suggest positive associations between high intakes of dietary
SFAs, MUFAs, total cholesterol and the development of stomach cancer in a large population-based
case-control study in China. The findings might shed some light on potential etiological roles of dietary
Nutrients 2019, 11, 1730 13 of 15
fatty acids and cholesterol on stomach cancer, and consequently, the possible dietary intervention
could be implemented to prevent stomach cancer in Chinese population.
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